Valuation: HighTide Therapeutics, Inc.

Market Cap 1.3B 1.5B 192M 168M 155M 143M 271M 18.28B 276M 1.85B 726M 9B 720M 704M 30.96B P/E 2024
-1.41x
P/E 2025 -5.19x
Enterprise Value 924M 1.07B 136M 119M 110M 101M 193M 12.99B 196M 1.31B 516M 6.4B 511M 500M 22B EV / Sales 2024
-
EV / Sales 2025 -
Free-Float
44.17%
Yield 2024 *
-
Yield 2025 -
1 day+2.33%
1 week-4.01%
Current month-1.87%
1 month-4.36%
3 months-26.54%
6 months-2.95%
Current year-10.85%
1 week 2.32
Extreme 2.32
2.73
1 month 2.32
Extreme 2.32
3.2
Current year 1.8
Extreme 1.8
4.72
1 year 1.8
Extreme 1.8
4.72
3 years 0.72
Extreme 0.72
13.18
5 years 0.72
Extreme 0.72
13.18
10 years 0.72
Extreme 0.72
13.18
Manager TitleAgeSince
Chief Executive Officer 56 31/12/2010
Director of Finance/CFO 57 30/11/2022
Chief Tech/Sci/R&D Officer - 01/02/2026
Director TitleAgeSince
Director/Board Member 68 29/11/2020
Director/Board Member 61 -
Chairman 56 -
Date Insider Type Main position Quantity % Market Cap.
04-29Other

Director

1,800,000 0.3151%
03-31Other

Chief Executive Officer

8,325,618 1.4572%
31/03/25Other

Chief Executive Officer

3,960,550 0.7694%
Change 5-day change 1-year change 3-year change Capi.($)
+2.33%-4.01%-25.28% - 192M
+1.84%-0.66%+59.82%+92.96% 54.88B
-4.14%-8.06%+58.96%+118.67% 54.63B
-2.24%+3.59%+17.75%+477.47% 25.06B
-1.60%-6.21%-18.96%-15.21% 23.14B
+2.43%+1.06%+42.44%-1.27% 19.87B
-3.19%0.00%+35.60%-26.98% 17.55B
-6.84%+2.18%+195.12%+357.18% 16.5B
+8.74%+3.51%+51.91%+726.40% 15.75B
-1.05%+1.16%+25.95%+194.27% 14.2B
Average -0.37%-0.65%+44.33%+213.72% 24.18B
Weighted average by Cap. -0.89%-1.45%+51.20%+177.14%

Financials

2024 2025
Net sales - -
Net income -382M -441M -56.31M -49.25M -45.43M -41.96M -79.61M -5.37B -80.95M -543M -213M -2.65B -211M -207M -9.09B -245M -283M -36.13M -31.6M -29.15M -26.92M -51.08M -3.45B -51.94M -348M -137M -1.7B -136M -133M -5.84B
Net Debt -413M -477M -60.88M -53.25M -49.12M -45.37M -86.08M -5.81B -87.53M -587M -230M -2.86B -229M -224M -9.83B -376M -435M -55.45M -48.5M -44.74M -41.32M -78.4M -5.29B -79.72M -535M -210M -2.61B -208M -204M -8.96B
Logo HighTide Therapeutics, Inc.
HighTide Therapeutics Inc is a biopharmaceutical company specializing in the discovery, development and commercialization of multifunctional, multi-targeted therapies for the treatment of metabolic and digestive diseases. The Company has developed a product pipeline of multiple product candidates in-house, covering many indications in metabolic and digestive diseases among which, some are at clinical-stage. The Company’s core product, HTD1801 (berberine ursodeoxycholate), a new molecular entity, is a gut-liver anti-inflammatory metabolic modulator which targets multiple pathways pivotal to metabolic regulation, including those associated with metabolic and digestive diseases. The Company conducts operations in the United States, Mainland China, Hong Kong and Australia.
Employees
51
Date Price Change Volume
10/07/26 HK$2.630 +2.33% 77,000
09/07/26 HK$2.570 -1.91% 100,000
08/07/26 HK$2.620 +0.38% 64,000
07/07/26 HK$2.610 -3.33% 246,500
06/07/26 HK$2.700 -1.46% 23,000

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 2511 Stock